OpenToolslogo
ToolsExpertsSubmit a Tool
AdvertiseLearn AI
  1. home
  2. news
  3. tags
  4. fda

fda

10+ articles
2025AIAI ChipsAI integrationAnthropic
Loading news...

Related Topics

2025AIAI ChipsAI integrationAnthropicBiotechClaude AIElon MuskGoogle GeminiHealthcare Technology

Most Read

1
Elon Musk Dreams Big with Neuralink's Vision and Hearing Restoration
2
HHS Pulls Plug on Anthropic's Claude AI Amid Controversy
3
Neuralink Nabs Former FDA Director David McMullen to Drive Medical Affairs Forward
4
Thoughts Turn Into Action: Neuralink's Breakthrough Brain Chip Lets the Paralyzed Control Robotic Limbs
5
Stock Movers: Tech Giants and Biotech Firms Make Big Waves!

Stay in the loop

Weekly updates on tools, models, and the companies building them.

Subscribe free

Footer

Company name

The right AI tool is out there. We'll help you find it.

LinkedInX

Knowledge Hub

  • News
  • Resources
  • Newsletter
  • Blog
  • AI Tool Reviews
  • YouTube Summary
  • YouTube Transcript Generator

Industry Hub

  • AI Companies
  • AI Tools
  • AI Models
  • MCP Servers
  • AI Tool Categories
  • Top AI Use Cases

For Builders

  • Submit a Tool
  • Experts & Agencies
  • Advertise
  • Compare Tools
  • Favourites

Legal

  • Privacy Policy
  • Terms of Service

© 2026 OpenTools - All rights reserved.

Elon Musk Dreams Big with Neuralink's Vision and Hearing Restoration

Elon Musk recently highlighted Neuralink's groundbreaking potential to restore vision and hearing through brain-computer interfaces. With devices already implanted in 21 paralysis patients, Neuralink's ambition mirrors Blindsight's visual cortex method. Musk is optimistic about direct auditory and visual cortex stimulation, and the journey continues with challenges and exciting milestones ahead.

Apr 5
Elon Musk Dreams Big with Neuralink's Vision and Hearing Restoration

HHS Pulls Plug on Anthropic's Claude AI Amid Controversy

Dive into the clash between Anthropic and the Trump administration as the Department of Health and Human Services yanks Anthropic's Claude AI from federal use. From Pentagon disputes to legal challenges, explore the implications for national security, government AI procurement, and innovation in the tech sector.

Mar 3
HHS Pulls Plug on Anthropic's Claude AI Amid Controversy

Neuralink Nabs Former FDA Director David McMullen to Drive Medical Affairs Forward

Elon Musk's Neuralink hits the headlines with a strategic hire, tapping former FDA official David McMullen to head its medical affairs. Known for overseeing neurological device regulations during his FDA tenure, McMullen's move signifies Neuralink's commitment to strengthen regulatory compliance and accelerating clinical advancements in brain-computer interface technology. As the company progresses with human trials for patients with severe paralysis, this appointment is stirring discussions about ethical implications and regulatory dynamics.

Dec 10
Neuralink Nabs Former FDA Director David McMullen to Drive Medical Affairs Forward

Thoughts Turn Into Action: Neuralink's Breakthrough Brain Chip Lets the Paralyzed Control Robotic Limbs

Neuralink's cutting-edge brain-computer interface (BCI) technology allows paralyzed people to control robotic limbs with their minds. It's a leap toward autonomy for those with severe conditions like ALS.

Dec 4
Thoughts Turn Into Action: Neuralink's Breakthrough Brain Chip Lets the Paralyzed Control Robotic Limbs

Stock Movers: Tech Giants and Biotech Firms Make Big Waves!

Explore the latest trends in the stock market as NVIDIA surges on AI chip demand, while Tesla falters with revised production guidance. Learn why biotech stocks are buzzing with the FDA's new drug approval, and see what's driving the retail sector's holiday gains.

Dec 1
Stock Movers: Tech Giants and Biotech Firms Make Big Waves!

Neuralink's October Trial: From Thoughts to Text!

Get ready for a revolutionary step as Elon Musk's Neuralink plans an October clinical trial to convert brain thoughts into text. Aimed at aiding those with speech impairments, this FDA-approved study will decode imagined speech, rewriting communication as we know it. While promising vast benefits, it also raises notable ethical and societal questions.

Sep 20
Neuralink's October Trial: From Thoughts to Text!

AI Steps Up: Revolutionizing Drug Safety Amid Pharma's Talent Crisis

In the face of a talent shortfall, the pharmaceutical industry is turning to AI for drug safety workflows. By utilizing AI technologies like machine learning and natural language processing, the sector is enhancing efficiency in pharmacovigilance processes, tackling regulatory demands, and addressing the scarcity of skilled professionals. The integration of AI in drug safety promises quicker data processing, minimal manual tasks, and improved risk assessments, setting a new standard in the pharma industry.

Sep 16
AI Steps Up: Revolutionizing Drug Safety Amid Pharma's Talent Crisis

AI Revolutionizes Drug Discovery as FDA Eases Pathway for Reduced Animal Testing

The FDA has unveiled draft guidance that encourages the use of AI in drug development, signaling a transformative shift in pharmaceuticals. Aiming to reduce animal testing by 2025, this framework focuses on enhancing safety, efficacy, and quality in drug discovery and regulatory processes. Industry insiders are optimistic as AI stands to speed up approvals and improve ethical standards in pharmaceutical innovation.

Sep 2
AI Revolutionizes Drug Discovery as FDA Eases Pathway for Reduced Animal Testing

FDA Embraces AI: New Tool to Fast-Track Scientific Reviews Unveiled

The FDA has announced the launch of an AI tool designed to significantly cut down the time required for scientific reviews. This move marks a major milestone in healthcare and pharmaceuticals, allowing faster approvals and streamlined processes. The AI tool is expected to enhance efficiency and accuracy in the review process, positioning the FDA at the forefront of technology integration in regulatory affairs.

Jun 4
FDA Embraces AI: New Tool to Fast-Track Scientific Reviews Unveiled

Neuralink Secures $650M in Series E Funding: A Leap Forward in Neurotechnology

Neuralink, Elon Musk's pioneering brain-computer interface company, has successfully closed a $650 million Series E funding round, catapulting its valuation to approximately $9 billion. With investments from key players like ARK Invest and Sequoia Capital, the company's landmark achievement comes as it kicks off human clinical trials and receives a breakthrough device designation from the FDA. This development is set to accelerate the fusion of technology and neuroscience, offering potential treatments for severe paralysis and beyond.

Jun 3
Neuralink Secures $650M in Series E Funding: A Leap Forward in Neurotechnology